CureVac

Primary contact
Frankfurt, Germany; Cambridge, Massachusetts, United States

CureVac is a biopharmaceutical company that is harnessing messenger RNA (mRNA) for medical purposes. The principle is promising: use natural mRNA as a data carrier to instruct the human body to produce its own proteins to fight a wide range of diseases. CureVac's lead programme is dedicated to the development of active immunotherapies (based on its RNActive technology) for the treatment of prostate cancer and non-small cell lung cancer. Also, the company is developing prophylactic vaccines and adjuvants to address infectious diseases.
Primary contact
Frankfurt, Germany; Cambridge, Massachusetts, United States

Funding 💰

Total $420M
Select investors dievini Hopp Biotech Holdingi, Eli Lilly, Baillie Gifford, Bill & Melinda Gates Foundation, Northview LifeSciences
Last update: May 13, 2018